Heart failure biomarkers and prediction of early left ventricle remodeling after acute coronary syndromes

IF 2.5 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinical biochemistry Pub Date : 2024-08-31 DOI:10.1016/j.clinbiochem.2024.110814

Alberto Cordero , Irene Velasco , Emilio Flores , José Mª López-Ayala , Sonia Sánchez-Munuera , Mª Pilar Muñoz-Villalba , Alejandro Selva-Mora , Francisco Galán-Giménez , Rafael de la Espriella , Julio Nuñez

{"title":"Heart failure biomarkers and prediction of early left ventricle remodeling after acute coronary syndromes","authors":"Alberto Cordero , Irene Velasco , Emilio Flores , José Mª López-Ayala , Sonia Sánchez-Munuera , Mª Pilar Muñoz-Villalba , Alejandro Selva-Mora , Francisco Galán-Giménez , Rafael de la Espriella , Julio Nuñez","doi":"10.1016/j.clinbiochem.2024.110814","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Several biomarkers are characteristically elevated in patients with acute heart failure (AHF). Our hypothesis was they could predict early changes in left ventricular (LV) characteristics in acute coronary syndrome (ACS) patients. The objective of this study was two-fold: a) compare circulating concentrations of NT-pro BNP, CA-125, ST2, galectin-3 and pro-adrenomedullin among 4 groups of individuals (healthy controls; patients with ACS without AHF; patients with ACS and AHF and patients admitted for AHF); and b) evaluate whether these biomarkers predict adverse LV remodeling and ejection fraction changes in ACS.</p></div><div><h3>Methods</h3><p>6 biomarkers (NT-pro BNP, CA-125, ST2, galectin-3, pro-adrenomedullin and C-reactive) were measured within the first 48 h of admission. Echocardiograms were performed during admission and at 3 months. Variables associated with LV end-diastolic volume (EDV) and ejection fraction (LVEF) change were assessed by multivariate linear regression.</p></div><div><h3>Results</h3><p>We analyzed 51 patients with ACS, 16 with AHF and, 20 healthy controls. NT-pro BNP and ST2 concentrations were elevated at similar values in patients admitted for AHF and ACS complicated with HF but CA-125 concentrations were higher in AHF patients. NT-pro BNP concentrations were positively correlated with CA-125 (rho = 0.58; p < 0.001), ST2 (rho = 0.58; p < 0.001) and galectin-3 (rho = 0.37; p < 0.001)</p><p>Median change (median days was 83 days after) in EDV and LVEF was 5 %. CA-125 concentrations were positively associated to LV EDV change (β-coefficient 1.56) and negatively with LVEF trend (β-coefficient = −0.86). No other biomarker predicted changes in EDV or LVEF.</p></div><div><h3>Conclusions</h3><p>CA-125 correlates with early LV remodeling and LVEF deterioration in ACS patients.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912024001085","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Several biomarkers are characteristically elevated in patients with acute heart failure (AHF). Our hypothesis was they could predict early changes in left ventricular (LV) characteristics in acute coronary syndrome (ACS) patients. The objective of this study was two-fold: a) compare circulating concentrations of NT-pro BNP, CA-125, ST2, galectin-3 and pro-adrenomedullin among 4 groups of individuals (healthy controls; patients with ACS without AHF; patients with ACS and AHF and patients admitted for AHF); and b) evaluate whether these biomarkers predict adverse LV remodeling and ejection fraction changes in ACS.

Methods

6 biomarkers (NT-pro BNP, CA-125, ST2, galectin-3, pro-adrenomedullin and C-reactive) were measured within the first 48 h of admission. Echocardiograms were performed during admission and at 3 months. Variables associated with LV end-diastolic volume (EDV) and ejection fraction (LVEF) change were assessed by multivariate linear regression.

Results

We analyzed 51 patients with ACS, 16 with AHF and, 20 healthy controls. NT-pro BNP and ST2 concentrations were elevated at similar values in patients admitted for AHF and ACS complicated with HF but CA-125 concentrations were higher in AHF patients. NT-pro BNP concentrations were positively correlated with CA-125 (rho = 0.58; p < 0.001), ST2 (rho = 0.58; p < 0.001) and galectin-3 (rho = 0.37; p < 0.001)

Median change (median days was 83 days after) in EDV and LVEF was 5 %. CA-125 concentrations were positively associated to LV EDV change (β-coefficient 1.56) and negatively with LVEF trend (β-coefficient = −0.86). No other biomarker predicted changes in EDV or LVEF.

Conclusions

CA-125 correlates with early LV remodeling and LVEF deterioration in ACS patients.

Abstract Image

查看原文本刊更多论文

心力衰竭生物标志物和急性冠状动脉综合征后左心室早期重塑的预测。

简介急性心力衰竭（AHF）患者体内有几种生物标志物明显升高。我们的假设是，它们可以预测急性冠状动脉综合征（ACS）患者左心室特征的早期变化。本研究的目的有两个：a）比较四组人群（健康对照组、无急性心力衰竭的急性冠状动脉综合征患者、急性心力衰竭的急性冠状动脉综合征患者和因急性心力衰竭入院的患者）中 NT-pro BNP CA-125、ST2、galectin-3 和 pro-adrenomedullin 的循环浓度；b）评估这些生物标志物是否能预测急性冠状动脉综合征患者左心室的不良重构和射血分数的变化。方法：在入院后 48 小时内测量 6 种生物标志物（NT-pro BNP、CA-125、ST2、galectin-3、pro-肾上腺髓质素和 C-反应）。在入院期间和 3 个月时进行超声心动图检查。通过多变量线性回归评估了与左心室舒张末期容积（EDV）和射血分数（LVEF）变化相关的变量：我们分析了 51 名 ACS 患者、16 名 AHF 患者和 20 名健康对照者。AHF患者和ACS并发HF患者的NT-pro BNP和ST2浓度升高值相似，但AHF患者的CA-125浓度更高。NT-pro BNP 浓度与 CA-125 呈正相关（rho = 0.58；p 结论：NT-pro BNP 浓度与 CA-125 呈正相关：CA-125与ACS患者早期左心室重构和LVEF恶化相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical biochemistry 医学-医学实验技术

CiteScore

5.10

自引率

0.00%

发文量

151

审稿时长

25 days

期刊介绍： Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.